Pinetree Therapeutics, Inc
PineTree Therapeutics Inc. is a preclinical stage biotechnology company dedicated to developing disruptive therapies in oncology and other diseases. The company focuses on innovative platforms such as AbReptor and Taer-Tab, which involve bi-specific and multi-specific antibody technologies aimed at degrading membrane-bound and extracellular proteins, and targeting difficult-to-target receptors on cancer cells. With a team of accomplished scientific and business leaders, PineTree Therapeutics is committed to advancing targeted biologic therapeutics for unmet medical needs, collaborating with major pharmaceutical companies like AstraZeneca, and supporting cutting-edge research in immuno-oncology and immunology. The company is based in Cambridge, MA, and emphasizes a collaborative, innovative, and inclusive work environment.
Industries
Nr. of Employees
small (1-50)
Pinetree Therapeutics, Inc
Cambridge, Massachusetts, United States, North America
Products
Multispecific antibody platform for targeted protein degradation
A modular multispecific antibody development platform engineered to engage targets and promote degradation of membrane-bound and extracellular proteins for therapeutic intervention.
Bispecific antibody platform targeting challenging cancer receptors
Bispecific antibody platform engineered to engage unique and difficult-to-target receptors expressed on cancer cells across multiple tumor types to enable targeted therapeutic approaches.
Multispecific antibody platform for targeted protein degradation
A modular multispecific antibody development platform engineered to engage targets and promote degradation of membrane-bound and extracellular proteins for therapeutic intervention.
Bispecific antibody platform targeting challenging cancer receptors
Bispecific antibody platform engineered to engage unique and difficult-to-target receptors expressed on cancer cells across multiple tumor types to enable targeted therapeutic approaches.
Services
Licensing and strategic collaborations for preclinical candidates
Option and licensing agreements and strategic partnerships to advance preclinical therapeutic candidates into external clinical development and commercialization.
Collaborative research in large-scale data analysis
Collaborative projects that apply machine learning and large-dataset analysis to support biotherapeutic discovery and biomarker identification.
Licensing and strategic collaborations for preclinical candidates
Option and licensing agreements and strategic partnerships to advance preclinical therapeutic candidates into external clinical development and commercialization.
Collaborative research in large-scale data analysis
Collaborative projects that apply machine learning and large-dataset analysis to support biotherapeutic discovery and biomarker identification.
Expertise Areas
- Targeted protein degradation
- Bispecific and multispecific antibody engineering
- Preclinical oncology development
- Antibody discovery and protein engineering
Key Technologies
- Multispecific/bispecific antibody engineering
- Antibody-mediated targeted protein degradation
- ELISA and Meso Scale Discovery immunoassays
- Multi-color flow cytometry